FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895593384> ?p ?o ?g. }

• W2895593384 endingPage "455" @default.
• W2895593384 startingPage "439" @default.
• W2895593384 abstract "Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled trial (TANGO II) was conducted from 2014 to 2017 to evaluate the efficacy/safety of meropenem-vaborbactam monotherapy versus best available therapy (BAT) for CRE.A total of 77 patients with confirmed/suspected CRE infection (bacteremia, hospital-acquired/ventilator-associated bacterial pneumonia, complicated intra-abdominal infection, complicated urinary tract infection/acute pyelonephritis) were randomized, and 47 with confirmed CRE infection formed the primary analysis population (microbiologic-CRE-modified intent-to-treat, mCRE-MITT). Eligible patients were randomized 2:1 to meropenem-vaborbactam (2 g/2 g over 3 h, q8h for 7-14 days) or BAT (mono/combination therapy with polymyxins, carbapenems, aminoglycosides, tigecycline; or ceftazidime-avibactam alone). Efficacy endpoints included clinical cure, Day-28 all-cause mortality, microbiologic cure, and overall success (clinical cure + microbiologic eradication). Safety endpoints included adverse events (AEs) and laboratory findings.Within the mCRE-MITT population, cure rates were 65.6% (21/32) and 33.3% (5/15) [95% confidence interval (CI) of difference, 3.3% to 61.3%; P = 0.03)] at End of Treatment and 59.4% (19/32) and 26.7% (4/15) (95% CI of difference, 4.6% to 60.8%; P = 0.02) at Test of Cure;.Day-28 all-cause mortality was 15.6% (5/32) and 33.3% (5/15) (95% CI of difference, - 44.7% to 9.3%) for meropenem-vaborbactam versus BAT, respectively. Treatment-related AEs and renal-related AEs were 24.0% (12/50) and 4.0% (2/50) for meropenem-vaborbactam versus 44.0% (11/25) and 24.0% (6/25) for BAT. Exploratory risk-benefit analyses of composite clinical failure or nephrotoxicity favored meropenem-vaborbactam versus BAT (31.3% [10/32] versus 80.0% [12/15]; 95% CI of difference, - 74.6% to - 22.9%; P < 0.001).Monotherapy with meropenem-vaborbactam for CRE infection was associated with increased clinical cure, decreased mortality, and reduced nephrotoxicity compared with BAT.NCT02168946.The Medicines Company." @default.
• W2895593384 created "2018-10-12" @default.
• W2895593384 creator A5001524626 @default.
• W2895593384 creator A5013718821 @default.
• W2895593384 creator A5019585781 @default.
• W2895593384 creator A5019596297 @default.
• W2895593384 creator A5022863734 @default.
• W2895593384 creator A5023544619 @default.
• W2895593384 creator A5026731919 @default.
• W2895593384 creator A5030219128 @default.
• W2895593384 creator A5031748923 @default.
• W2895593384 creator A5031752979 @default.
• W2895593384 creator A5038285556 @default.
• W2895593384 creator A5039296570 @default.
• W2895593384 creator A5039694085 @default.
• W2895593384 creator A5040669754 @default.
• W2895593384 creator A5044157939 @default.
• W2895593384 creator A5045368960 @default.
• W2895593384 creator A5049148828 @default.
• W2895593384 creator A5054900639 @default.
• W2895593384 creator A5063736715 @default.
• W2895593384 creator A5065586040 @default.
• W2895593384 creator A5078360933 @default.
• W2895593384 creator A5084939652 @default.
• W2895593384 creator A5089200309 @default.
• W2895593384 date "2018-10-01" @default.
• W2895593384 modified "2023-10-14" @default.
• W2895593384 title "Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial" @default.
• W2895593384 cites W1433753708 @default.
• W2895593384 cites W1833417126 @default.
• W2895593384 cites W1968310807 @default.
• W2895593384 cites W2008500841 @default.
• W2895593384 cites W2042164350 @default.
• W2895593384 cites W2071637551 @default.
• W2895593384 cites W2080551841 @default.
• W2895593384 cites W2096579515 @default.
• W2895593384 cites W2097312339 @default.
• W2895593384 cites W2118519564 @default.
• W2895593384 cites W2145111808 @default.
• W2895593384 cites W2164697816 @default.
• W2895593384 cites W2168409658 @default.
• W2895593384 cites W2317448158 @default.
• W2895593384 cites W2500501420 @default.
• W2895593384 cites W2565726837 @default.
• W2895593384 cites W2579703015 @default.
• W2895593384 cites W2620821467 @default.
• W2895593384 cites W2737095712 @default.
• W2895593384 cites W2790077090 @default.
• W2895593384 cites W2793280651 @default.
• W2895593384 cites W4293242440 @default.
• W2895593384 doi "https://doi.org/10.1007/s40121-018-0214-1" @default.
• W2895593384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6249182" @default.
• W2895593384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30270406" @default.
• W2895593384 hasPublicationYear "2018" @default.
• W2895593384 type Work @default.
• W2895593384 sameAs 2895593384 @default.
• W2895593384 citedByCount "298" @default.
• W2895593384 countsByYear W28955933842019 @default.
• W2895593384 countsByYear W28955933842020 @default.
• W2895593384 countsByYear W28955933842021 @default.
• W2895593384 countsByYear W28955933842022 @default.
• W2895593384 countsByYear W28955933842023 @default.
• W2895593384 crossrefType "journal-article" @default.
• W2895593384 hasAuthorship W2895593384A5001524626 @default.
• W2895593384 hasAuthorship W2895593384A5013718821 @default.
• W2895593384 hasAuthorship W2895593384A5019585781 @default.
• W2895593384 hasAuthorship W2895593384A5019596297 @default.
• W2895593384 hasAuthorship W2895593384A5022863734 @default.
• W2895593384 hasAuthorship W2895593384A5023544619 @default.
• W2895593384 hasAuthorship W2895593384A5026731919 @default.
• W2895593384 hasAuthorship W2895593384A5030219128 @default.
• W2895593384 hasAuthorship W2895593384A5031748923 @default.
• W2895593384 hasAuthorship W2895593384A5031752979 @default.
• W2895593384 hasAuthorship W2895593384A5038285556 @default.
• W2895593384 hasAuthorship W2895593384A5039296570 @default.
• W2895593384 hasAuthorship W2895593384A5039694085 @default.
• W2895593384 hasAuthorship W2895593384A5040669754 @default.
• W2895593384 hasAuthorship W2895593384A5044157939 @default.
• W2895593384 hasAuthorship W2895593384A5045368960 @default.
• W2895593384 hasAuthorship W2895593384A5049148828 @default.
• W2895593384 hasAuthorship W2895593384A5054900639 @default.
• W2895593384 hasAuthorship W2895593384A5063736715 @default.
• W2895593384 hasAuthorship W2895593384A5065586040 @default.
• W2895593384 hasAuthorship W2895593384A5078360933 @default.
• W2895593384 hasAuthorship W2895593384A5084939652 @default.
• W2895593384 hasAuthorship W2895593384A5089200309 @default.
• W2895593384 hasBestOaLocation W28955933841 @default.
• W2895593384 hasConcept C104317684 @default.
• W2895593384 hasConcept C126322002 @default.
• W2895593384 hasConcept C141071460 @default.
• W2895593384 hasConcept C168563851 @default.
• W2895593384 hasConcept C185592680 @default.
• W2895593384 hasConcept C197934379 @default.
• W2895593384 hasConcept C2775933652 @default.
• W2895593384 hasConcept C2775992322 @default.
• W2895593384 hasConcept C2776968632 @default.
• W2895593384 hasConcept C2777027569 @default.
• W2895593384 hasConcept C2777058267 @default.

• next